Drug Trial News

RSS

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

Tikcro Technologies Ltd. today reported results for the fourth quarter and year ended December 31, 2009.

17 Apr 2010

Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL

In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. described further encouraging trends observed in a previously reported Phase 2 study of KNS-760704 (dexpramipexole) in ALS.

17 Apr 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

Repligen expects total revenue of $21.0M for fiscal year 2010

Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.

16 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

InterMune, Inc. today announced results of all three cohorts from a 15-day Phase 1b multiple-ascending-dose (MAD) study of low doses of danoprevir (also known as RG7227 and ITMN-191) boosted by low-dose ritonavir (RTV) in patients chronically infected with hepatitis C virus (HCV) genotype-1.

16 Apr 2010

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis C virus required multiple mutations across two separate proteins in order to establish resistance to SCY-635. The majority of HCV drugs on the market and in development require only one targeted viral mutation to establish resistance.

16 Apr 2010

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported promising in vitro data for IDX320, an HCV protease inhibitor, demonstrating potent and selective antiviral activity in multiple genotypes, or strains, of the virus.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

16 Apr 2010

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.

16 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress™ 2010, the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

16 Apr 2010

LOTS results of Myozyme in older children and adults with Pompe disease published

Genzyme Corp. today announced that the results from its Late-Onset Treatment Study have been published in today's New England Journal of Medicine. The study was undertaken to evaluate the safety and efficacy of Myozyme (alglucosidase alfa) in older children and adults with Pompe disease.

16 Apr 2010

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Emisphere Technologies, Inc. today announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technologies is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen Technology.

16 Apr 2010

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, initiated the Company's first clinical trial site in its randomized, single blind, placebo-controlled, Phase 2 clinical trial of ADXS11-001 for the treatment of cervical intraepithelial neoplasia.

16 Apr 2010

Drug Trial News

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL

RegeneRx Biopharmaceuticals proposes common stock public offering

Repligen expects total revenue of $21.0M for fiscal year 2010

VisEn Medical expands FMT imaging platform

Results of study comparing REMICADE to azathioprine for Crohn's disease published

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

LOTS results of Myozyme in older children and adults with Pompe disease published

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News